Smoking negatively impacts the clinical, microbiological, and immunological treatment response of young adults with Grade C periodontitis

J Periodontal Res. 2022 Dec;57(6):1116-1126. doi: 10.1111/jre.13049. Epub 2022 Sep 1.

Abstract

Objective: This study aimed to investigate the influence of smoking on clinical, microbiological and immunological parameters in young adult with stage III-IV Grade C periodontitis after full-mouth ultrasonic debridement (FMUD) associated with Amoxicillin and Metronidazole (AMX + MTZ), comparing smokers (PerioC-Y-Smk) with non-smokers (PerioC-Y-NSmk).

Materials and methods: Fifteen PerioC-Y-NSmk and 14 PerioC-Y-Smk patients underwent FMUD associated with AMX + MTZ for 10 days. All parameters were collected at baseline and 3 and 6 months after treatment. Plaque index (PI), bleeding on probing (BoP), probing depth (PD), clinical attachment level (CAL)- the primary variable-, and gingival recession (GR) were clinically assessed. The impact of PI on CAL change at 6-month was verified by a regression analysis. Samples of the subgingival biofilm was collected for detection of levels of Aggregatibacter actinomycetemcomitans (A. actinomycetemcomitans), Porphyromonas gingivalis (P.gingivalis), Tannerella forsythia (T. forsythia), and Fusobacterium nucleatum ssp (F. nucleatum), and were analyzed by real-time qPCR; gingival crevicular fluid was collected for detection of levels of interleukin (IL)-1β, IL-4, IL-6, IL-10, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ, which were analyzed using an enzyme immunoassay.

Results: PerioC-Y-Smk had significantly higher PI, BOP, and GR at baseline compared to non-smokers (p < .05). PerioC-Y-Smk presented higher PD, CAL, and GR at 3 and 6 months (p < .05) compared with PerioC-Y-NSmk in the same periods; PI negatively affected CAL gain in PerioC-Y-NSmk at 6-month follow-up (p = .052) and did not impact on clinical response in PerioC-Y-Smk (p = .882). Lower levels of IFN-γ, IL1-β, and IL-4 were observed at 3 months in the PerioC-Y-NSmk (p < .05) compared with PerioC-Y-Smk. Lower proportions of P. gingivalis were observed in PerioC-Y-NSmk at baseline and at 3 months (p < .05) and lower proportions of F. nucleatum were observed at 6 months, in the PerioC-Y-NSmk (p < .05).

Conclusions: PerioC-Y-Smk presents an unfavorable clinical, microbiological, and immunological response after 3 and 6 months after FMUD associated with AMX + MTZ.

Clinical relevance: Smoking worsens periodontal condition of young treated adults presenting stage III/IV Grade C periodontitis.

Keywords: aggressive periodontitis; antimicrobials; periodontal debridement; smoking.

MeSH terms

  • Aggregatibacter actinomycetemcomitans
  • Amoxicillin / therapeutic use
  • Follow-Up Studies
  • Gingival Crevicular Fluid
  • Humans
  • Interleukin-4*
  • Metronidazole / therapeutic use
  • Periodontitis* / drug therapy
  • Porphyromonas gingivalis
  • Smoking / adverse effects
  • Young Adult

Substances

  • Interleukin-4
  • Amoxicillin
  • Metronidazole